The Bob Harrington Show

Three editors of cardiology journals -- Drs Harrington, Yancy, and Nallamothu -- discuss the challenges of maintaining quality during the COVID-19 surge in submissions.

Hematologist Mary Cushman discusses arterial and venous thrombosis issues with SARS-CoV-2 and the role of anticoagulation.

Bob Harrington asks Michelle Albert why mortality rates are so high in minority communities, and whether COVID-19 will lead to meaningful changes in health and social inequities.

'They fancy themselves free. And no one will ever be free so long as there are pestilences,' wrote Camus in 'The Plague', which Abraham Verghese sees as relevant to our collective experience of COVID-19.

Cardiologist Lisa Rosenbaum seeks meaning in her work as a physician and correspondent for the New England Journal of Medicine, a quest first started by her grandfather who was also a physician-writer.

Bob Harrington and Mike Gibson continue their review of 2019 with the 'hottest trial of the year' and what to expect in healthcare in 2020.

'It's like we're in the '90s again.' Drs Gibson and Harrington review top cardiology trials on revascularization, lipid management, and antithrombotics in part 1 of their annual wrap-up.

A family history of sudden death was the impetus for author Sandeep Juahar's fascination with the heart, which led to a career in cardiology and his latest book Heart: A History.

Fewer black men are going into medicine today than in 1978. Drs Harrington and Capers discuss how to increase diversity in medicine and why it's important for caregivers to reflect the population they treat.

Optimal medical therapy and recent advances show that heart failure is preventable and not obligatory, Clyde Yancy tells Bob Harrington.

It's not all dire. Tait Shanafelt, MD, is witnessing improvement and momentum in the field of clinician wellness. Learn about his journey from hematology to chief wellness officer.

Volunteering at a VA hospital was the first step in biostatistician Frank Harrell's illustrious career in cardiovascular research.

Despite the vastness of available data, don't forget the basics, warns biostatistician Frank Harrell in this conversation with Bob Harrington.

Drs Harrington and Yeh discuss the pros, cons, and cautions of using Twitter in the cardiovascular community.

Drs Harrington and Joynt Maddox discuss the move from volume-based to performance-based payment models and how to develop evidence-based quality metrics that make clinical sense.

Drs Harrington and Gibson discuss burning issues in medicine, including artificial intelligence, social media, wearable tech, and the new hypertension guidelines.

Trials on PCSK9 inhibitors, antiplatelets, anticoagulants, and even catheter ablation of atrial fibrillation are among Drs Harrington and Gibson's picks for what to look for in 2018.

A recent viewpoint by Dr Bhatt against public reporting of PCI outcomes garnered a lot of support in the cardiology community and beyond. Dr Harrington asks how it can be done better.

In this annual tradition, Drs Harrington and Gibson discuss their picks for the top cardiology trials of the year, covering PCSK9 inhibitors, anti-inflammatory and anthithrombotic drugs, and PCI.

Drs Harrington and Kesselheim discuss the varied reasons why prescription drugs are so pricey and whether policies can interrupt this alarming trend.